BD wins approval for generic, injectable antiemetic

Ondansetron injection is third product in BD Simplist line

FRANKLIN LAKES, N.J. — The Food and Drug Administration has approved the latest drug in BD's Simplist line, the company said Thursday.

BD announced the approval of ondansetron injection in the 4 mg/2 mL strength, an injectable drug used to prevent nausea and vomiting after surgery. The drug is currently on the FDA's drug shortage list due to recent increases in demand and supply issues faced by other manufactures, BD said.

"We're proud to be expanding our BD Simplist products with a drug like ondansetron injection, USP, which is in high demand among clinicians and fills a need for an intervention that can be administered quickly," BD Rx president Mark Sebree said. "As we establish our product line with a third drug approval, we are seeing even further indication of the positive responses to our new BD Simplist prefilled injectables, especially among repeat customers."

BD announced its plan to manufacture generic drugs through its BD Rx division, and its BD Simplist product line currently contains two other products.

 

Login or Register to post a comment.